Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
jaktinib + glucocorticoids
- Development stage
- Unknown
- Lead developer
- Suzhou Zelgen Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Jaktinib + glucocorticoids is a combination therapy being evaluated as a first-line treatment for grade II-IV acute graft-versus-host disease (aGVHD). The regimen consists of jaktinib (also known as gecacitinib), a small molecule pan-Janus kinase (JAK) inhibitor, and glucocorticoids (typically methylprednisolone). Jaktinib works by inhibiting the JAK-STAT signaling pathway, which is central to the production and action of pro-inflammatory cytokines that drive the immune-mediated damage in aGVHD. Glucocorticoids provide complementary immunosuppression by binding to the glucocorticoid receptor and modulating gene expression to reduce inflammation. This combination is currently being studied in a Phase 1/2 clinical trial led by the First Affiliated Hospital of Zhejiang University to determine the recommended Phase 2 dose and assess preliminary efficacy and safety in patients following allogeneic hematopoietic stem cell transplantation.
- Other names
- Gecacitinib + glucocorticoidsJaktinib + methylprednisolone
02
Targets
JAK3 (Janus kinase 3)JAK2 (Janus kinase 2)GR (Glucocorticoid receptor)FLT3 (Fms related receptor tyrosine kinase 3)JAK1 (Janus kinase 1)TYK2 (Tyrosine kinase 2)KIT (c-KIT proto-oncogene receptor tyrosine kinase)ACVR1 (Activin receptor type I)
Beyond the preview
Go deeper on jaktinib + glucocorticoids.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on jaktinib + glucocorticoids.